UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 63

Sortiert nach

The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol

Gastroenterology (New York, N.Y. 1943), 2017-11, Vol.153 (5), p.1295-1303

2017

Volltextzugriff (PDF)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2319-2333

2001

Volltextzugriff (PDF)

The Durability of EUS-Guided Chemoablation of Mucinous Pancreatic Cysts: A Long-Term Follow-Up of the CHARM trial

Clinical gastroenterology and hepatology, 2022-02, Vol.20 (2), p.e326-e329

2022

Volltextzugriff (PDF)

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Journal of clinical oncology, 1998-09, Vol.16 (9), p.2986-2999

1998

Volltextzugriff (PDF)

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Clinical cancer research, 1999-09, Vol.5 (9), p.2366-2373

1999

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Journal of clinical oncology, 2005-06, Vol.23 (17), p.3912-3922

2005

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer

Cancer research (Chicago, Ill.), 1994-04, Vol.54 (7), p.1690-1694

1994

Volltextzugriff (PDF)

Phase I study of phenylacetate administered twice daily to patients with cancer

Cancer, 1995-06, Vol.75 (12), p.2932-2938

1995

Volltextzugriff (PDF)

Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Cancer, 1995-08, Vol.76 (3), p.453-462

1995

Volltextzugriff (PDF)

Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of “Hormone-Refractory” Prostate Cancer

JNCI : Journal of the National Cancer Institute, 1994-02, Vol.86 (3), p.222-227

1994

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

Journal of clinical oncology, 2002-10, Vol.20 (19), p.4074-4082

2002

Volltextzugriff (PDF)

Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine

Journal of clinical pharmacology, 1995-04, Vol.35 (4), p.368-373

1995

Volltextzugriff (PDF)

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal

Clinical cancer research, 1998-01, Vol.4 (1), p.37-44

1998

Volltextzugriff (PDF)

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-Acid glycoprotein

Cancer research (Chicago, Ill.), 1998-08, Vol.58 (15), p.3248-3253

1998

Volltextzugriff (PDF)

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin

Journal of clinical oncology, 1995-09, Vol.13 (9), p.2223-2229

1995

Volltextzugriff (PDF)

Suramin-induced neutropenia

European journal of cancer (1990), 1996-08, Vol.32 (9), p.1534-1539

1996

Volltextzugriff (PDF)

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma

Clinical cancer research, 2000-04, Vol.6 (4), p.1302-1313

2000

Volltextzugriff (PDF)

Adaptive control with feedback strategies for suramin dosing

Clinical pharmacology and therapeutics, 1992-07, Vol.52 (1), p.11-23

1992

Volltextzugriff (PDF)

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

Annals of oncology, 1996-11, Vol.7 (9), p.939-944

1996

Volltextzugriff (PDF)

Is Alcohol Required for Effective Pancreatic Cyst Ablation? The Prospective Randomized CHARM Trial: 2017 ACG Governors Award for Excellence in Clinical Research: 773

The American journal of gastroenterology, 2017-10, Vol.112, p.S432

2017

Volltextzugriff (PDF)

Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target

Pharmacology & therapeutics (Oxford), 1999-05, Vol.82 (2), p.285-292

1999

Volltextzugriff (PDF)

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6

Clinical cancer research, 2003-02, Vol.9 (2), p.562-570

2003

Volltextzugriff (PDF)

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma

Blood, 1996-08, Vol.88 (4), p.1188-1197

1996

Volltextzugriff (PDF)

Continuous Infusion of the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients With B-Cell Lymphoma: A Phase I Study

Blood, 1995-06, Vol.85 (12), p.3457-3465

1995

Volltextzugriff (PDF)

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer

Journal of the National Medical Association, 1997-09, Vol.89 (9), p.622-628

1997

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(59)
Reviews
(2)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(63)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

The Durability of EUS-Guided Chemoablation of Mucinous Pancreatic Cysts: A Long-Term Follow-Up of the CHARM trial

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer

Phase I study of phenylacetate administered twice daily to patients with cancer

Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of “Hormone-Refractory” Prostate Cancer

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-Acid glycoprotein

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin

Suramin-induced neutropenia

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma

Adaptive control with feedback strategies for suramin dosing

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

Is Alcohol Required for Effective Pancreatic Cyst Ablation? The Prospective Randomized CHARM Trial: 2017 ACG Governors Award for Excellence in Clinical Research: 773

Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma

Continuous Infusion of the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients With B-Cell Lymphoma: A Phase I Study

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer

Suchergebnisse filtern